Skip to main content
. Author manuscript; available in PMC: 2012 Jan 14.
Published in final edited form as: AIDS. 2011 Jan 14;25(2):211–220. doi: 10.1097/QAD.0b013e328340fdf8

Table 2.

Life expectancy, costs, and cost-effectiveness of strategies in primary analysis

Initial regimen Quality-adjusted LE (discounted years) Life expectancy (discounted years) Average number of ODs per person Total lifetime costs (discounted 2009USD) Incremental cost-effectiveness ratio ($ per QALY)
zidovudine + lamivudine + nevirapine 10.47 12.39 2.22 7,711 Base
stavudine + lamivudine + nevirapine 10.31 12.51 2.17 7,824 Dominated
tenofovir + lamivudine + nevirapine 11.08 12.54 2.18 8,348 1,045
zidovudine + lamivudine + efavirenz 10.69 12.72 2.07 8,748 Dominated
 
tenofovir + lamivudine + efavirenz 11.27 12.82 2.03 9,479 5,950